Gene
FANCC
FANCC is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (2), Actionable biomarkers (2), Trial mentions (28), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention FANCC. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 8 of 11,460 | 0.07% |
| 2022 | 4 of 8,285 | 0.05% | 11 of 13,598 | 0.08% |
| 2021 | 4 of 8,692 | 0.05% | 12 of 15,045 | 0.08% |
| 2020 | 4 of 7,640 | 0.05% | 11 of 14,459 | 0.08% |
| 2019 | 2 of 7,300 | 0.03% | 4 of 12,159 | 0.03% |
| 2018 | 3 of 6,927 | 0.04% | 8 of 11,854 | 0.07% |
| 2017 | 2 of 6,558 | 0.03% | 6 of 11,595 | 0.05% |
Showing 10 of 37 years.
Assay-provider ledger (2)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Not a company | Clinical validationAnalytical validation | 1 | February 01, 2019 |
| The Cancer Genome Atlas (TCGA) | Not a company | Clinical validationAnalytical validation | 1 | February 01, 2019 |
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| FANCC oncogenic mutation | CISPLATIN | response-associated | No disease recorded | Cancer Genome Interpreter |
| FANCC deletion | CISPLATIN | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (28)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04550494 | Trial eligibility (AACT) |
| NCT00352976 | Trial eligibility (AACT) |
| NCT05687110 | Trial eligibility (AACT) |
| NCT05967286 | Trial eligibility (AACT) |
| NCT02401347 | Trial eligibility (AACT) |
Showing 5 of 28 trial mentions.
Target-disease associations (343)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 46 XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX gonadal dysgenesis | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX ovotesticular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XX testicular disorder of sex development | endocrine system disease | Mouse knockout (IMPC) |
| 46,XY complete gonadal dysgenesis | cardiovascular disease | Mouse knockout (IMPC) |
Showing 5 of 343 associations.
Vendor sourcing (112)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v4.1.0 dataset. Predicted Consequence/Location: Missense variant. The majority of the known disease-causing variant... | View ClinVar record SCV007607340.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The FANCC c.1151A>G; p.His384Arg variant (rs577302082), to our knowledge, is not reported in the medical literature but is reported in ClinVar (Variation ID:... | View ClinVar record SCV007331947.1 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | FANCC | View trial NCT03061188 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein functio... | View ClinVar record SCV000673285.5 |
Showing 5 of 112 sourcing records.
Trial-cited literature (90)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1). | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 55 |
| Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia. | Blood advances | 2025 | 12 |
| Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. | Nature medicine | 2023 | 131 |
| The role of iron in the pathogenesis of endometriosis: a systematic review. | Human reproduction open | 2023 | 69 |
| Genotype-phenotype and outcome associations in patients with Fanconi anemia: the National Cancer Institute cohort. | Haematologica | 2023 | 51 |
Showing 5 of 90 papers.
Protein variant mentions (83)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A132G | 1 | 2015 | PMID 25741868 |
| p.A284V | 1 | 2015 | PMID 25741868 |
| p.A301T | 1 | 2015 | PMID 25741868 |
| p.A325T | 1 | 2015 | PMID 25741868 |
| p.A325V | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
Showing 5 of 83 variants.
Literature-extracted relations (6)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. | 2020 |
| Drug-Related Side Effects and Adverse Reactions | Disease | associate |
Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients. | 2018 |
| Non-Muscle Invasive Bladder Neoplasms | Disease | associate |
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. | 2015 |
| Anemia, Hemolytic | Disease | associate |
The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. | 2004 |
| Anemia, Hemolytic | Disease | associate |
A common mutation in the FACC gene causes Fanconi anaemia in Ashkenazi Jews. | 1993 |
Showing 5 of 6 relation assertions.
Organizations publishing (139)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 7 | 2016 to 2023 |
| Memorial Sloan Kettering Cancer Center | Hospital | 7 | 2016 to 2023 |
| Dana-Farber Cancer Institute | Other | 5 | 2015 to 2022 |
| Mass General Brigham | Hospital | 5 | 2015 to 2022 |
| Harvard Medical School | Academic | 4 | 2015 to 2023 |
Showing 5 of 139 organizations.
Where FANCC appears
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- genetic, familial or congenital disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- phenotype
- reproductive system or breast disease
- urinary system disease
324 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.